NCT05262010 2026-01-16
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
National Vaccine and Serum Institute, China
Phase 3 Recruiting
National Vaccine and Serum Institute, China
Shanghai Bovax Biotechnology Co., Ltd.
Shanghai Bovax Biotechnology Co., Ltd.